IRADIMED CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.9 USD | -1.09% |
|
+2.12% | -11.73% |
| Apr. 03 | IRadimed Files $75 Million Common Stock Shelf Registration | MT |
| Feb. 08 | Transcript : IRadimed Corporation, Q4 2023 Earnings Call, Feb 08, 2024 |
Financials (USD)
| Sales 2024 * | 72.56M | Sales 2025 * | 81.19M | Capitalization | 531M |
|---|---|---|---|---|---|
| Net income 2024 * | 17M | Net income 2025 * | 20M | EV / Sales 2024 * | 7.31 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.54 x |
| P/E ratio 2024 * |
30.4
x | P/E ratio 2025 * |
25.9
x | Employees | 148 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on IRADIMED CORPORATION
More press releases
| 1 day | -1.09% | ||
| 1 week | +2.12% | ||
| Current month | -4.75% | ||
| 1 month | -3.10% | ||
| 3 months | -7.28% | ||
| 6 months | +10.03% | ||
| Current year | -11.73% |
1 week
40.18
42.82
1 month
40.1844.67
Current year
40.1849.00
1 year
36.1251.04
3 years
25.4055.92
5 years
14.4255.92
10 years
6.2655.92
| Managers | Title | Age | Since |
|---|---|---|---|
Roger Susi
CEO | Chief Executive Officer | 70 | 92-06-30 |
John F. Glenn
DFI | Director of Finance/CFO | 62 | 22-06-19 |
Chris Williamson
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony F. Vuoto
BRD | Director/Board Member | 73 | 16-03-28 |
Monty K. Allen
BRD | Director/Board Member | 71 | 13-12-31 |
James Hawkins
BRD | Director/Board Member | 68 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.19% | 27 M€ | -4.16% | - | |
| 0.08% | 29 M€ | -3.61% | ||
| 0.00% | 9 M€ | +5.94% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 41.9 | -1.09% | 61,624 |
| 24-04-22 | 42.36 | +3.32% | 30,918 |
| 24-04-19 | 41 | +1.59% | 51,681 |
| 24-04-18 | 40.36 | -0.27% | 28,705 |
| 24-04-17 | 40.47 | -1.36% | 35,407 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patientâs vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gausses.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
41.9
USD
Average target price
62.5
USD
Spread / Average Target
+49.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.73% | 531M | |
| +72.39% | 12.32B | |
| -18.22% | 7.96B | |
| +16.84% | 7.25B | |
| +5.88% | 5.84B | |
| +8.16% | 5.11B | |
| +19.97% | 4.28B | |
| -19.84% | 4B | |
| -42.79% | 2.15B | |
| +1.49% | 2.01B |
- Stock Market
- Equities
- IRMD Stock
